PCCA's ExoBlue: The Science Fueling Personalized Skincare's Future

HOUSTON, TX – May 27, 2026 – PCCA, a key supplier for the pharmaceutical compounding industry, today launched ExoBlue™, a sophisticated cosmetic base that signals a significant step forward in the rapidly expanding personalized skincare market. The new base is designed to empower compounding pharmacists to create highly customized, next-generation dermatological preparations, moving beyond simple vehicles to offer a complex, evidence-backed formulation as a starting point.

This launch comes as the global personalized skincare market, valued at over $26 billion in 2025, is projected to nearly double to over $50 billion by 2035. Consumers are increasingly rejecting one-size-fits-all products, instead demanding solutions tailored to their unique skin biology, concerns, and lifestyle. ExoBlue™ is positioned to directly address this demand, providing pharmacists with a powerful tool to compete in the burgeoning world of bespoke beauty.

The Science of Synergy

What sets ExoBlue™ apart from standard compounding bases is its intrinsic design as a synergistic system. Rather than being an inert carrier, the base itself is powered by a framework of five potent, well-researched cosmetic technologies. PCCA asserts that the combination creates an effect greater than the sum of its parts, a claim echoed by the company's leadership.

“With the launch of ExoBlue, we’ve brought together copper peptides, exosome-inspired technology and specialized zinc hyaluronate complexes where the total impact of the formula is greater than that of any individual component,” stated PCCA Vice President of Research and Development Daniel Banov, RPh, MS. “It is this synergy that truly differentiates ExoBlue from standard topical skincare bases.”

The core components include:

• Acetyl Hexapeptide-8: Often known by its commercial name Argireline, this peptide is renowned for its ability to reduce the appearance of expression wrinkles by limiting muscle activity, offering a topical approach to smoother-looking skin.

• GHK-Copper Peptide PURE (GHK-Cu): A naturally occurring peptide that plays a vital role in skin remodeling and wound healing. It is known to stimulate the production of both collagen and elastin, key proteins for maintaining skin firmness and elasticity, while also acting as a potent antioxidant.

• Zinc Hyaluronate (HA-Zn): This compound cleverly merges the profound hydrating power of hyaluronic acid with the anti-inflammatory and healing properties of zinc. The zinc ions also help stabilize the hyaluronic acid molecule, providing longer-lasting moisturization and barrier support, making it ideal for sensitive or compromised skin.

• Centella Asiatica-Derived Exosomes: Leveraging one of the most popular ingredients in modern skincare, CICA, this technology uses nanometric vesicles to deliver bioactive compounds deep into the skin. These exosomes act as cellular messengers, stimulating collagen synthesis, reducing inflammation, and accelerating the skin's natural repair processes.

By pre-formulating these high-performance actives into an elegant base, PCCA simplifies the process for pharmacists to build even more complex and targeted therapies. It provides a foundation that already addresses key aspects of skin health—hydration, repair, texture, and the appearance of aging—before any additional active pharmaceutical ingredients are even added.

Empowering Pharmacists in a Booming Market

The introduction of ExoBlue™ is a strategic move that equips compounding pharmacists to become central figures in the personalized beauty movement. Traditionally, the creation of custom skincare in a pharmacy setting involved adding active ingredients to relatively simple cream or gel bases. ExoBlue™ fundamentally changes this dynamic by providing a high-tech foundation that already aligns with the most advanced trends in cosmetic science.

“ExoBlue is about the power of the combination,” said PCCA CEO Gus Bassani, PharmD. “By bringing these multiple technologies together into one easy-to-use and elegant base, we are giving our members the tool to create highly customized dermatologic preparations that align with the most modern trends in beauty and skin health.”

This allows local pharmacies to offer a level of customization and scientific sophistication previously reserved for high-end specialty brands or dermatological clinics. They can now formulate products that specifically target a patient's concerns—be it acne, rosacea, hyperpigmentation, or advanced signs of aging—using a base that is already working to improve overall skin health and appearance. This capability positions them to capture a share of a market driven by consumers who are highly educated about ingredients and demand proven efficacy.

Beyond the Hype: The Promise of Evidence-Based Results

In a beauty industry often saturated with marketing hype and unsubstantiated claims, PCCA is backing the launch of ExoBlue™ with clinical data. The company conducted an eight-week cosmetic-use evaluation of the base on its own, without any additional active ingredients. The results were notable: 72 percent of participants showed visible improvement in the appearance of their skin within just four weeks.

Furthermore, investigators conducting the assessment observed improvements in the appearance of both moderate and deep wrinkles over the course of the study. “Observing visible improvements in such a high percentage of study participants in just four weeks speaks to the potential of this innovative system,” Banov noted.

While the full, peer-reviewed methodology of the cosmetic evaluation is proprietary, presenting such data from the outset lends significant credibility to the base itself. It demonstrates that ExoBlue™ is not merely a passive vehicle but an active contributor to skin enhancement. For consumers weary of investing in products that don't deliver, and for pharmacists who build their reputation on trust and results, this evidence-based approach is a critical differentiator. It provides a layer of assurance that the final compounded product begins with a foundation that is already clinically evaluated for aesthetic improvement, enhancing the potential of any further customization.